臨床外科71巻4号

2016年04月発行

特集 大腸癌肝転移—最新の治療ストラテジー 肝切除法・治療戦略のトピックス

切除不能大腸癌肝転移に対するconversion chemotherapy

著者： 別府透¹² 今井克憲¹ 坂本快郎¹ 鶴田豊¹ 陶山浩一³ 馬場秀夫¹

所属機関： ¹熊本大学大学院消化器外科学 ²熊本大学附属病院消化器癌集学的治療学 ³熊本大学附属病院外来化学療法センター

ページ範囲：P.468 - P.473

【ポイント】
◆切除不能大腸癌肝転移をconversion chemotherapy後に肝切除することで長期生存が望める．
◆conversion chemotherapyとしては，奏効率の高い抗EGFR抗体併用化学療法やFOLFOXIRI＋ベバシズマブが期待されている．
◆適切なconversion chemotherapyを臨床試験により確立する必要がある．

参考文献

1）Alberts SR, Horvath WL, Sternfeld WC, et al：Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer：a North Central Cancer Treatment Group phase II study. J Clin Oncol 23：9243-9249, 2005

2）Ismaili N：Treatment of colorectal liver metastases. World J Surg Oncol 9：154, 2011

3）Poston GJ, Adam R, Alberts S, et al：OncoSurge：a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 23：7125-7134, 2005

4）大腸癌研究会（編）：大腸癌治療ガイドライン医師用2014年版．金原出版，2014

5）Adam R, Wicherts DA, de Haas RJ, et al：Complete pathologic response after preoperative chemotherapy for colorectal liver metastases：myth or reality? J Clin Oncol 26：1635-1641, 2008

6）Adam R, Delvart V, Pascal G, et al：Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy：a model to predict long-term survival. Ann Surg 240：644-657, 2004

7）Beppu T, Miyamoto Y, Sakamoto Y, et al：Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol 21（Suppl 3）：405-413, 2014

8）Lam VW, Spiro C, Laurence JM, et al：A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 19：1292-1301, 2012

9）Quan D, Gallinger S, Nhan C, et al：The role of liver resection for colorectal cancer metastases in an era of multimodality treatment：a systematic review. Surgery 151：860-870, 2012

10）Beppu T, Emi Y, Tokunaga S, et al：Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab（KSCC0802 study）. Anticancer Res 34：6655-6662, 2014

11）Oki E, Emi Y, Miyamoto Y, et al；Kyushu Study Group of Clinical Cancer（KSCC）：Phase II trial of S-1 and oxaliplatin plus cetuximab for colorectal cancer patients with initially unresectable or not optimally resectable liver metastases（KSCC1002）. Ann Surg Oncol 22（Suppl 3）：1067-1074, 2015

12）Fong Y, Fortner J, Sun RL, et al：Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer：analysis of 1001 consecutive cases. Ann Surg 230：309-318, 1999

13）Beppu T, Sakamoto Y, Hasegawa K, et al：A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection：multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19：72-84, 2012

14）Therkildsen C, Bergmann TK, Henrichsen-Schnack T, et al：The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer：A systematic review and meta-analysis. Acta Oncol 53：852-864, 2014

15）Beppu T, Sakamoto Y, Imai K, et al：A patient with colorectal liver metastases with para-aortic regional lymph node metastases who survived for 7 years. Int Canc Conf J 3：153-157, 2014

16）Folprecht G, Grothey A, Alberts S, et al：Neoadjuvant treatment of unresectable colorectal liver metastases：correlation between tumor response and resection rates. Ann Oncol 16：1311-1319, 2005

17）Jones RP, Hamann S, Malik HZ, et al：Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer 50：1590-1601, 2014

18）Tournigand C, André T, Achille E, et al：FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer：a randomized GERCOR study. J Clin Oncol 22：229-237, 2004

19）Colucci G, Gebbia V, Paoletti G, et al；Gruppo Oncologico Dell'Italia Meridionale：Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer：a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23：4866-4875, 2005

20）Barone C, Nuzzo G, Cassano A, et al：Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 97：1035-1039, 2007

21）Vauthey JN, Pawlik TM, Ribero D, et al：Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24：2065-2072, 2006

22）Rubbia-Brandt L, Lauwers GY, Wang H, et al：Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56：430-439, 2010

23）Folprecht G, Gruenberger T, Bechstein WO, et al：Tumour response and secondary resectability of colorectal liver metastases following neoadjavant chemotherapy with cetuximab：the CELIM randomized phase 2 trial. Lancet Oncol 11：38-47, 2010

24）Folprecht G, Gruenberger T, Bechstein W, et al：Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept（CELIM study）. Ann Oncol 25：1018-1025, 2014

25）Petrelli F, Barni S：Anti-EGFR agents for liver metastases. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases：a meta-analysis. Int J Colorectal Dis 27：997-1004, 2012

26）Ye LC, Liu TS, Ren L, et al：Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31：1931-1938, 2013

27）Saltz LB, Clarke S, Díaz-Rubio E, et al：Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer：a randomized phase III study. J Clin Oncol 26：2013-2019, 2008

28）Wong R, Cunningham D, Barbachano Y, et al：A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22：2042-2048, 2011

29）Ribero D, Wang H, Donadon M, et al：Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110：2761-2767, 2007

30）Heinemann V, von Weikersthal LF, Decker T, et al：FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer（FIRE-3）：a randomised, open-label, phase 3 trial. Lancet Oncol 15：1065-1075, 2014

31）Schwartzberg LS, Rivera F, Karthaus M, et al：PEAK：a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin（mFOLFOX6）or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32：2240-2247, 2014

32）Venook AND, Lenz HJ, et al. CALGB/SWOG 80405：phase III trial of irinotecan/5-FU/leucovorin（FOLFIRI）or oxaliplatin/5-FU/leucovorin（mFOLFOX6）with bevacizumab（BV）or Cetuximab（CET）for patients（pts）with KRAS wild-type（wt）untreated metastatic adenocarcinoma of the colon or rectum（MCRC）. J Clin Oncol 32：5s, 2014（suppl；abstr LBA）, 2015

33）Gruenberger T, Bridgewater J, Chau I, et al：Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer：the OLIVIA multinational randomised phase II trial. Ann Oncol 26：702-708, 2015

34）Loupakis F, Cremolini C, Masi G, et al：Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371：1609-1618, 2014

35）Yanhong D, Huabin H, Guanjian L, et al：FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type. J Clin Oncol 33, 2015（suppl；abstr TPS3624）

36）Piessevaux H, Buyse M, Schlichting M, et al：Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 31：3764-3775, 2013

37）Ricotta R, Vanzulli A, Moroni M, et al：Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab. Clin Colorectal Cancer 12：45-53, 2013

38）Nagai N, Beppu T, Sakamoto Y, et al：Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in the induction chemotherapy for colorectal liver metastases. Anticancer Res 34：5529-5535, 2014

39）Hayashi H, Beppu T, Sakamoto Y, et al：Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases. Am J Cancer Res 5：1225-1233, 2015

40）Adam R, Pascal G, Castaing D, et al：Tumor progression while on chemotherapy：a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240：1052-1061, 2004

41）ViganòL, Capussotti L, De Rosa G, et al：Liver resection for colorectal metastases after chemotherapy：impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 258：731-740, 2013

42）de Hass RJ, Wicherts DA, Flores E, et al：R1 resection by necessity for colorectal liver metastases：is it still a contraindication to surgery? Ann Surg 248：626-637, 2008

43）Aksoy E, Aliyev S, Taskin HE, et al：Clinical scenarios associated with local recurrence after laparoscopic radiofrequency thermal ablation of colorectal liver metastases. Surgery 154：748-752, 2013

44）Mima K, Beppu T, Chikamoto A, et al：Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. Int J Clin Oncol 18：847-855, 2013

45）Rubbia-Brandt L, Audard L, Sartoretti P, et al：Severe hepatic sinusoidal obstruction associated with Oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Onco 15：460-466, 2004

46）Nakano H, Oussoultzoglou E, Rosso E, et al：Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247：118-124, 2008

47）Shin NY, Kim MJ, Lim JS, et al：Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22：864-871, 2012

48）Tamandl D, Klinger M, Eipeldauer S, et al：Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 18：421-430, 2011

49）Imai K, Emi Y, Iyama KI, et al：Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol 40：559-566, 2014

50）Cauchy F, Aussilhou B, Dokmak S, et al：Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg 256：746-752, 2012

51）Takatsuki M, Tokunaga S, Uchida S, et a；Kyushu Study Group of Clinical Cancer（KSCC）：Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases：A multicenter study. Eur J Surg Oncol. 2015 Nov 22［Epub ahead of print］

52）Takahashi T, Shibata Y, Tojima Y, et al：Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan：ROOF study. Int J Clin Oncol 18：335-342, 2013